News

Florida Cancer Specialists Strengthens Oncology Services Team

Florida Cancer Specialists Strengthens Oncology Services Team

Florida Cancer Specialists Expands Its Oncology Team

Florida Cancer Specialists & Research Institute (FCS) is thrilled to announce the addition of highly skilled medical professionals, Dr. Eric Gershman and Dr. Susan Morgan, to its esteemed statewide practice. Their arrival marks a significant enhancement of oncology and hematology services offered in the thriving communities served by FCS.

New Additions to the Team

Dr. Gershman will focus on providing cancer care to patients in the Palm Coast area, while Dr. Morgan will serve patients in Naples. Their unique expertise and compassionate approach to medicine will undoubtedly benefit the families and communities they serve. Nathan H. Walcker, the CEO of FCS, expressed excitement about the contributions that both doctors will bring, stating that their experience and dedication will enhance the accessible world-class oncology care available in these regions.

Meet Dr. Eric Gershman

Dr. Eric Gershman has a rich background in oncology, having completed his medical degree from the University Central Del Caribe in Puerto Rico. He honed his skills during his residency at Louisiana State University and further specialized in hematology and oncology at New York University Medical Center. With a decade of experience, Dr. Gershman is well-equipped to deliver personalized patient care that addresses individual needs while utilizing advanced treatment methodologies.

Introducing Dr. Susan Morgan

Dr. Susan Morgan is equally impressive, with her medical degree obtained from the Uniformed Services University of the Health Sciences in Maryland. She completed her residency training at Tripler Army Medical Center in Honolulu and pursued a fellowship at Walter Reed Army Medical Center. Dr. Morgan brings over two decades of experience within the field and is well-respected for her commitment and care towards her patients and their families.

The FCS Commitment to Quality Care

Florida Cancer Specialists prides itself on being at the forefront of cancer care by providing access to a multitude of clinical trials. These are critical pathways for patients seeking the latest therapies, as FCS is known for its participation in developing new cancer drugs that eventually gain approval. The work performed by FCS physicians often places them at the top of various national rankings.

Celebrating Four Decades of Excellence

As FCS approaches its 40th anniversary, the organization continues to forge stronger relationships within the community while striving for innovation in patient care. Their reputation is built not only on providing advanced treatments but also on maintaining a focus on compassionate care through personalized relationships with patients. The dedication demonstrated by FCS staff ensures that each patient receives the highest standard of service.

Frequently Asked Questions

What is the significance of the additions of Dr. Gershman and Dr. Morgan to FCS?

Their expertise enhances the comprehensive oncology services available in the Palm Coast and Naples areas, improving patient care and access to treatments.

Where did Dr. Gershman receive his medical education?

Dr. Gershman obtained his medical degree from the University Central Del Caribe in Puerto Rico and completed his residency at Louisiana State University.

What types of treatments does Florida Cancer Specialists offer?

FCS provides various treatments including targeted therapies, genomic-based treatment, immunotherapy, and access to clinical trials for new therapies.

How does Florida Cancer Specialists maintain its standards in cancer care?

FCS maintains high standards of care by employing trained physicians, participating in clinical trials, and actively pursuing innovative treatment options.

What impact has FCS made in the field of oncology?

FCS has developed a national reputation for excellence in cancer care, significantly contributing to clinical research and offering advanced treatments that lead to improved patient outcomes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading